The Dow Jones industrial average hiked by 113.31 points (i.e. 0.64%) at 17,904.48.
While Nasdaq added 25.58 points (i.e. 0.51%) at 5,055.55 and the S&P 500 gained 11.86 points (i.e. 0.57%) at 2,096.29. While you may be thinking the below fundamental news have already factored in prices, we feel the volumes have yet to evidence.
Talks between Athens, IMF & EU have been collapsed as Greece struggling to avoid its debt default.
Interest rate policy setting on the eve of Fed's monetary policy meeting, fed in this meeting may shed more light on much awaited rate hike noise for better clarity.
Deal negotiation for leading blue chip FMCG player P&G's beauty products business segment is likely to be taken over by Cotys for a staggering US$ 12 billion. As a result both share prices were surged up to lead index comprehensively and today some more gains are likely.
On the other hand another merger has been reported, Blackstone and Carlyle are making a joint bid for NCR in what would be the year's biggest leveraged buyout at more than $10 billion, including debt.
As the flurry of highly sensitive market making news is intensified, we see opportunities in index trading.
Yes, now is the time to reassess the US stocks and buy At-The-Money binary calls of NASDAQ futures at current levels of 4451.70 as well as Dow index at current levels at 17,900 levels.


US Economy Fueled by AI Investment Faces Rising Risks Ahead of Fed Meeting
AI-Driven Memory Chip Prices May Be Skewing U.S. Inflation Data, Fed Minutes Suggest
Global Bond Selloff Pressures Stocks as Rising Oil Prices Fuel Inflation Fears
Gold Cracks Below $4,500 as Safe-Haven Shine Fades; Technical Breakdown Signals Sell-on-Rallies Toward $4,000
Gold Cracks Below $4,500 as Safe-Haven Shine Fades; Technical Breakdown Signals Sell-on-Rallies Toward $4,000
Cuba needs a long-term solution to its energy crisis
Silver Sheds Gains in Gold’s Wake as Bears Probe Key $74.50 Support; Sell-on-Rallies Eyes $70
NHS shakeup: if it sounds like we’ve been here before, it’s because we have
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks 



